Gene therapy trial hopes to improve communication in angelman syndrome

NCT ID NCT07181837

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times

Summary

This study tests a new gene therapy called MVX-220 for people with Angelman syndrome, a genetic condition that affects the nervous system. The therapy is given as a single injection into the fluid around the brain and spinal cord. The trial will include 12 children (ages 4-8) and adults (ages 18-50) with specific genetic causes of Angelman syndrome. Researchers will check for side effects and measure changes in communication ability using a caregiver questionnaire.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANGELMAN SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Boston Children's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Cedars-Sinai Medical Center

    RECRUITING

    Los Angeles, California, 90048, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Rush University Medical Center

    RECRUITING

    Chicago, Illinois, 60612, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.